Breast cancer starts when a single cell in the breast acquires enough genetic damage to grow and divide without the normal checks that keep healthy cells in line. This doesn’t happen overnight. It’s a process that unfolds over years, sometimes decades, as cells accumulate mutations that disable their built-in safety systems one by one. Understanding what drives that process, from the first DNA error to a detectable tumor, can help make sense of risk factors, screening timelines, and why some cancers behave differently than others.
Where in the Breast It Begins
The breast is made up of lobes (milk-producing glands) connected by a network of tiny tubes called ducts that carry milk to the nipple. Most breast cancers start in the cells lining these ducts. A smaller number begin in the lobules themselves. The distinction matters because ductal and lobular cancers look and behave differently under a microscope, but recent research shows they may be more closely related than once thought.
A 2022 study in The American Journal of Surgical Pathology found that in tumors containing both ductal and lobular features, the lobular portion typically arose from ductal cells that lost a protein called E-cadherin, which normally acts like glue holding cells together. About 80% of these mixed tumors shared a common genetic driver in both components, suggesting that many lobular cancers begin as ductal growths that later change character. When cells lose E-cadherin, they stop sticking to their neighbors and instead grow in single-file lines, the hallmark pattern of lobular cancer.
The Genetic Damage That Triggers Growth
Every cell carries built-in instructions that tell it when to grow, when to stop, and when to self-destruct if something goes wrong. Cancer begins when mutations knock out these controls. Two categories of genes are central to the process.
Tumor suppressor genes act as brakes. The gene TP53, for example, produces a protein that monitors DNA for damage. When it detects a problem, it halts cell division and, if the damage is severe, triggers the cell to destroy itself. When TP53 is inactivated, damaged cells survive and keep dividing, passing their errors on to daughter cells. Another tumor suppressor, PTEN, helps regulate a signaling pathway that controls cell growth. Lose PTEN function, and cells receive a constant green light to proliferate.
DNA repair genes are equally important. Genes like BRCA1, BRCA2, CHEK2, and ATM are part of the cell’s maintenance crew, fixing broken or mismatched DNA before it can cause problems. When these genes don’t work properly, errors pile up with each round of cell division. Over time, some of those errors will land in genes that control growth, and the slide toward cancer accelerates.
Inherited Versus Acquired Mutations
Only about 5 to 10% of breast cancers are hereditary, meaning the person was born with a mutation that gave cancer a head start. In women under 35, that figure is higher, ranging from 25 to 40%. The most well-known inherited mutations are in BRCA1 and BRCA2, but several other genes carry significant risk, including TP53 (linked to Li-Fraumeni syndrome), PTEN (linked to Cowden syndrome), CDH1 (the E-cadherin gene, linked to lobular breast cancer), and STK11 (linked to Peutz-Jeghers syndrome). Moderate-risk genes like CHEK2, ATM, and PALB2 also increase susceptibility, though to a lesser degree.
The vast majority of breast cancers, roughly 90 to 95%, are sporadic. They arise from mutations acquired during a person’s lifetime through a combination of random copying errors during cell division, hormonal exposures, and environmental factors. A person with no family history and no inherited mutations can still develop breast cancer because enough random damage accumulated in the right genes at the wrong time.
How Hormones Fuel the Process
Estrogen and progesterone don’t directly mutate DNA the way radiation does, but they powerfully promote breast cancer by driving cell division. Every time a breast cell divides, there’s a small chance of a copying error. The more divisions, the more chances for a dangerous mistake.
These hormones work through receptors on and inside breast cells. When estrogen binds to its receptor on the cell surface, it triggers a rapid chain of signals that activate growth and survival pathways inside the cell. Progesterone does the same through its own receptor, activating cascades that promote proliferation and, in some cases, expand populations of cancer stem cells. This is why factors that increase lifetime estrogen exposure, such as early menstruation, late menopause, hormone replacement therapy, and obesity (fat tissue produces estrogen), are established risk factors.
About 70 to 80% of breast cancers are hormone receptor-positive, meaning the cancer cells still have estrogen or progesterone receptors and depend on these hormones to grow. This dependency is also what makes these cancers treatable with therapies that block hormone signaling.
The Slow Progression From Normal to Cancer
Breast cancer doesn’t leap from a normal cell to a malignant tumor in one step. It follows a gradual progression through identifiable stages, each representing more genetic damage and less normal cell behavior.
The first recognizable change is hyperplasia, where cells in a duct or lobule start dividing faster than usual but still look relatively normal. Next comes atypical hyperplasia, where the growing cells begin to look abnormal. Atypical ductal hyperplasia is defined as a small cluster of abnormal cells that resemble early cancer but measure 2 millimeters or less and occupy no more than two duct spaces. It’s essentially cancer’s dress rehearsal.
If the abnormal growth expands beyond that threshold, filling entire duct spaces and measuring more than 2 millimeters, it crosses into ductal carcinoma in situ (DCIS). At this stage, the cells are cancerous but haven’t broken through the wall of the duct into surrounding tissue. DCIS is sometimes called “stage zero” cancer. Not all DCIS progresses to invasive cancer, but some will, and predicting which cases will advance remains one of the harder problems in breast cancer care.
Invasive cancer begins when cells breach the duct or lobule wall and enter the surrounding breast tissue. From there, they can eventually reach blood vessels or lymph channels and spread to other parts of the body. This entire sequence, from the first abnormal cell to an invasive tumor large enough to detect on a mammogram, typically takes years to a decade or more.
How the Surrounding Tissue Helps or Hinders
A mutated cell doesn’t grow in isolation. The tissue around it, called the microenvironment, plays a significant role in whether a budding cancer survives or dies.
In healthy tissue, the immune system, structural fibers (the extracellular matrix), and neighboring cells like fibroblasts all work to suppress abnormal growth. Immune cells can recognize and destroy early cancer cells, and fibroblasts help maintain the tissue architecture that keeps cells in their proper place. At the earliest stages of tumor development, these defenses often succeed, and most mutated cells never become tumors.
But as cancer cells accumulate more mutations, they learn to manipulate their surroundings. They can recruit immune cells and fibroblasts and convert them from tumor suppressors into tumor promoters, creating a supportive niche. Fat cells in the breast also contribute. They release fatty acids, hormones, and inflammatory signals that can fuel cancer growth. This is one biological reason why obesity is a meaningful risk factor: more fat tissue in the breast means a more hospitable environment for early cancer cells.
Cancer Stem Cells and Why Tumors Come Back
Not all cells within a tumor are the same. A small subpopulation, known as cancer stem cells, appears to play an outsized role in both starting and sustaining tumors. These cells are highly efficient at forming new tumors and are often resistant to standard treatments.
Research published in the Proceedings of the National Academy of Sciences showed that cancer stem cells can be generated directly during the process of a cell becoming cancerous, appearing within about 24 hours and eventually making up roughly 10% of the tumor population. These stem cells secrete an inflammatory signal called IL-6 that can convert ordinary cancer cells back into stem cells, creating a self-sustaining loop. This dynamic equilibrium helps explain why tumors can shrink dramatically with treatment but later regrow: the bulk of the tumor dies, but the resistant stem cells survive and restart the process.
Environmental and Lifestyle Factors
Beyond genetics and hormones, a range of environmental exposures contribute to breast cancer initiation by either damaging DNA directly or disrupting the hormonal environment that drives cell growth.
- Alcohol: Classified as a known cause of breast cancer. It raises estrogen levels and produces compounds that can damage DNA.
- Air pollution: Exposure to fine particulate matter and heavy metals like lead, mercury, and cadmium is associated with increased risk. Living within two miles of industrial facilities that emit dioxins raises risk further.
- Night shift work: Long-term disruption of circadian rhythms from frequent night shifts is considered a cause of breast cancer. Even sleeping with a television or light on is linked to a 9% increase in risk.
- Endocrine disruptors: Chemicals that mimic or interfere with hormones pose the greatest risk during periods of rapid breast development: prenatal life, puberty, pregnancy, and the menopausal transition.
- Hair products: Regular use of permanent hair dyes or chemical straighteners is associated with higher risk, with Black women who use permanent dyes every five to eight weeks facing a 60% increased chance of developing breast cancer.
- Radiation: X-ray and gamma radiation are established breast carcinogens, which is why chest radiation at a young age (for example, during treatment for another cancer) is a recognized risk factor.
- Tobacco: Smoking is listed as a cause of breast cancer by the National Toxicology Program.
On the protective side, regular physical activity reduces the risk of premenopausal breast cancer, and adequate vitamin D levels are associated with lower risk. These factors don’t guarantee prevention, but they shift the odds by reducing the total burden of DNA damage and hormonal stimulation that breast cells experience over a lifetime.